BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.

Vaccine 200

Vaccine Pharma Companies Virus 200

BioPharma Drive: Drug Pricing

JULY 29, 2024

The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.

Pharma Companies 162

Pharma Companies Drugs Research 162

BioPharma Drive: Drug Pricing

SEPTEMBER 3, 2024

Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.

Pharma Companies 162

Pharma Companies 162

BioPharma Drive: Drug Pricing

SEPTEMBER 25, 2023

Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

Pharma Companies 147

Pharma Companies Drugs 147

Drug Patent Watch

SEPTEMBER 17, 2023

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the most supplementary protection certificates?

Pharma Companies 59

Pharma Companies Pharmaceuticals Drugs 59

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 147

Licensing Licensing Pharma Companies Treatment 147

BioPharma Drive: Drug Pricing

APRIL 14, 2025

Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR

Pharma Companies 130

Pharma Companies 130

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights.

Biosimilars 98

Biosimilars Pharma Companies Marketing Drugs 98

Drug Patent Watch

SEPTEMBER 18, 2022

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies 52

Pharma Companies Pharmaceuticals Drugs 52

Drug Patent Watch

SEPTEMBER 17, 2021

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies 52

Pharma Companies Pharmaceuticals Drugs 52

Drug Patent Watch

SEPTEMBER 16, 2020

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies 52

Pharma Companies Pharmaceuticals Drugs 52

BioPharma Drive: Drug Pricing

JULY 18, 2023

The pharma company, which will soon split off its generic drug unit, plans to repurchase up to $15 billion of its shares through the end of 2025.

Pharma Companies 130

Pharma Companies Drugs 130

Drug Target Review

DECEMBER 20, 2024

Smith states, weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways. As the industry gains more exposure to AIs real-world applications and the rigorous standards AI companies adhere to, trust will continue to grow.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Drug Patent Watch

MAY 13, 2025

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.

Licensing 91

Licensing Licensing Pharma Companies Pharmaceuticals 91

Metabolite Tales Blog

DECEMBER 12, 2024

The paper gives a useful insight into the most commonly used in vitro MetID practices across 26 pharma companies, and crucially reveals how effective these systems are at predicting circulating human metabolites. Hypha’s clients range from small through to large pharma companies.

Science 52

Science Pharma Companies Clinical Trials Clinical Development 52

Drug Patent Watch

APRIL 23, 2025

But what does this mean for pharma companies, investors, and patients? According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.

Marketing 82

Marketing Pharma Companies Pharmaceuticals Drugs 82

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Drug Patent Watch

FEBRUARY 2, 2021

In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…. DrugPatentWatch was featured in a recent article by Inc. The post DrugPatentWatch featured in Inc Magazine appeared first on DrugPatentWatch - Make Better Decisions.

Pharma Companies 91

Pharma Companies Drugs 91

Drug Patent Watch

JULY 25, 2023

In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,” Alexander R. Trimble, PhD, a prominent patent attorney, explores the… The post Filing Strategies for Maximizing Pharma Patents appeared first on DrugPatentWatch - Make Better Decisions.

Pharma Companies 91

Pharma Companies 91

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. .

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

Drug Target Review

JUNE 16, 2025

DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.

Disease 59

Disease Therapies Small Molecule Immune Response 59

Fierce BioTech

OCTOBER 25, 2023

The AI innovation race is on: Here are three strategies to ensure you’re not left behind | Biotech and pharma companies are using generative AI to improve business operations, marketing performance and research.

Pharma Companies 64

Pharma Companies Marketing Research 64

Drug Channels

OCTOBER 15, 2021

She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas). Today’s guest post comes from Jayne Hornung, Chief Clinical Officer at MMIT.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Pharma Companies Science 75

Advarra

MAY 21, 2025

What Pharma Sponsors Are Asking As sponsors prepare for ICH E6(R3), a few common questions have emerged: Where do we start? Many pharma companies are unsure how to begin aligning with the new expectations, especially around trial design and quality systems.

Pharma Companies 52

Pharma Companies FDA Trials Government 52

Fierce BioTech

SEPTEMBER 19, 2024

Listing Image QuartzListingLogo_250x190_norstella.png Listing Introduction Real-world data is essential to gaining insights into a patient’s diagnostic journey, but many pharma companies may not be using lab data, in particular, to its full potential. On Demand Start Date Tue, 10/29/2024 - 12:00

Treatment 52

Treatment Pharma Companies Disease 52

DrugBaron

OCTOBER 17, 2022

In practice, this looks much more like a traditional pharma company than a biotech. Global pharma companies, at least until recently, didn’t have “stories” linking assets but an uncorrelated pipeline of product candidates chosen for their individual value.

Pharma Companies 100

Pharma Companies Pharmaceuticals Drug Development Production 100

Fierce BioTech

OCTOBER 3, 2023

Discover how a top 10 pharma company is making strides in addressing this disparity by harnessing the power of H1's diversity insights to build an equitable clinical trial for cardiovascular disease.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Disease 52

DrugBank

JUNE 27, 2024

They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

H1 Blog

MAY 11, 2023

Omnichannel engagement for physician marketing is a powerful tool for biotechnology and pharma companies looking to increase reach and drive engagement among HCPs. By taking a tailored approach, pharma companies can ensure they’re offering meaningful information that resonates with each individual HCP.

Pharma Companies 52

Pharma Companies Marketing Treatment Pharmaceuticals 52

Fierce BioTech

SEPTEMBER 30, 2024

Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.

Pharma Companies 52

Pharma Companies Drug Development Marketing Drugs 52

Fierce BioTech

JULY 25, 2023

But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all. But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

The Pharma Data

OCTOBER 21, 2020

More than two dozen researchers and experts have penned a letter to HHS Secretary Alex Azar, National Institutes of Health (NIH) officials and pharma company executives, imploring them to shed more light on the clinical trial designs for federally funded COVID-19 vaccine studies. Source link.

Vaccine 52

Vaccine Government Trials Research 52

The Pharma Data

SEPTEMBER 22, 2020

Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m).

Pharma Companies 52

Pharma Companies Small Molecule Pharmaceutical Companies Disease 52

thought leadership

MAY 29, 2023

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. In this blog post, we'll explore some of the key challenges of specialty pharma drug development project management and discuss strategies for overcoming them.

Drug Development 52

Drug Development Pharma Companies Drugs Disease 52

The Connected Lab

APRIL 8, 2020

Companies such as Cyclica have developed software that matches the biophysical and biochemical properties of millions of molecules to the structures and properties of approximately 150,000 proteins to uncover molecules that are likely to bind to a target 2. 36 Pharma Companies Using Artificial Intelligence in Drug Discovery.”

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

PPD

JULY 13, 2023

Data from the survey has produced enlightening insights about the priorities of both large and small/mid-size pharma companies that can be used to guide business decisions. Patient diversity and site capacity issues emerge as key challenges for recruitment vendors to address.

Pharma Companies 52

Pharma Companies Clinical Trials Trials Clinical Research 52

Reprocell

NOVEMBER 1, 2022

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.

Animal Testing 52

Animal Testing Pharma Companies Laboratories Drug Development 52